NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a
biopharmaceutical company with a portfolio of commercial and
innovative, late-stage product candidates targeting neurological
diseases including rare disorders, today announced that the Board
of Directors unanimously elected Vlad
Coric, MD to the role of Chairman of the Board of Directors
following the retirement of Declan
Doogan, MD, effective immediately. The company also
announced the appointment of Matthew
Buten to the role of Chief Financial Officer (CFO) effective
by December 20, 2021, following the
retirement of CFO James Engelhart.
Both Dr. Doogan and Mr. Engelhart will continue to advise the
company after their retirement to ensure a smooth transition.
Current Director Michael Heffernan
has been appointed Lead Independent Director, effective
As a former managing director of Foresite Capital, Mr. Buten
brings more than 20 years of experience in healthcare investing as
well as 15 plus years as an advisor in investment banking and
strategic structuring of deals for both small and large
capitalization companies. Previously, Mr. Buten served as a
healthcare portfolio manager at Catapult/Millennium Partners.
Prior to joining Catapult/Millennium, he was co-founder and
co-manager of Sapphire Capital and a co-founder and a partner at
Argus Partners, both dedicated healthcare funds. He started his
early career in investment banking focused on mergers and
acquisitions, equity and debt financings and spin-offs with roles
as a Managing Director and Head of Healthcare Investment Banking
for Needham and Company and as a Director in Investment Banking at
Smith Barney. Mr. Buten earned a Bachelor of Science in Economics
(B.S.E.) from The Wharton School of the University of Pennsylvania.
Vlad Coric, MD, Chairman and
Chief Executive Officer of Biohaven commented, "We are excited to
welcome Matt to our executive leadership team as CFO as he brings
deep expertise in healthcare investment banking, venture capital,
corporate strategy and private equity to Biohaven. We also extend
our immense gratitude to Declan and Jim for their strategy and
leadership since the Company's inception that contributed to the
success of Biohaven."
Incoming CFO Matt Buten stated,
"Biohaven has established itself as a market leading
commercial-stage pharmaceutical company with the successful launch
of Nurtec® ODT and is at the beginning of its growth potential as a
company. I am excited to join Vlad and the entire team to help
advance novel therapeutics to patients. Biohaven is poised to
transform the field of neurologic treatments and I am looking
forward to contribute to its future success."
The retirements described in this announcement were not related
to any disagreement with the company on any matter relating to the
company's operations, policies or practices.
Biohaven is a commercial-stage biopharmaceutical company with a
portfolio of innovative, best-in-class therapies to improve the
lives of patients with debilitating neurological and
neuropsychiatric diseases, including rare disorders. Biohaven's
Neuroinnovation™ portfolio includes FDA-approved Nurtec ODT
(rimegepant) for the acute and preventive treatment of migraine and
a broad pipeline of late-stage product candidates across three
distinct mechanistic platforms: CGRP receptor antagonism for the
acute and preventive treatment of migraine; glutamate modulation
for obsessive-compulsive disorder, Alzheimer's disease, and
spinocerebellar ataxia; and MPO inhibition for amyotrophic lateral
sclerosis. More information about Biohaven is available
This news release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
The use of certain words, including "believe", "may" and "will" and
similar expressions, are intended to identify forward-looking
statements. These forward-looking statements involve substantial
risks and uncertainties, including statements that are based on the
current expectations and assumptions of Biohaven's management about
NURTEC ODT as an acute treatment for patients with migraine.
Various important factors could cause actual results or events to
differ materially from those that may be expressed or implied by
our forward-looking statements. Additional important factors to be
considered in connection with forward-looking statements are
described in the "Risk Factors" section of the Company's Annual
Report on Form 10-K filed with the Securities and Exchange
Commission on March 1, 2021 and the
Company's Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 9,
2021. The forward-looking statements are made as of this
date and Biohaven does not undertake any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
NURTEC and NURTEC ODT are registered trademarks of Biohaven
Pharmaceutical Ireland DAC.
Neuroinnovation is a trademark of Biohaven Pharmaceutical Holding
Chief Executive Officer
Sam Brown Inc.
View original content to download
SOURCE Biohaven Pharmaceutical Holding Company Ltd.